1. Home >
  2. M&A >
  3. Special Situations/Distressed >
  4. NKGen Acquires NKMax

M&A Deal Summary

NKGen Acquires NKMax

On September 9, 2025, NKGen acquired life science company NKMax

Acquisition Highlights
  • This is NKGen’s 1st transaction in the Life Science sector.
  • This is NKGen’s 1st transaction in South Korea.

M&A Deal Summary
Date 2025-09-09
Target NKMax
Sector Life Science
Buyer(s) NKGen
Deal Type Special Situations/Distressed

Target

NKMax

Seongnam-si, South Korea
NKMax is a biotechnology company that provides specialized immune healthcare solutions from diagnosis to treatment. It developed the NK Vue Kit, a precision immune diagnostic kit that measures immunity based on research on NK cells, which serve as the body's first line of defense. NKMax was formed in 2002 and is based in Seongnam-si, South Korea.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

NKGen

Santa Ana, California, United States
Category Company
Sector Life Science
DESCRIPTION

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Special Situations/Distressed M&A Deals 1 of 1
Country: South Korea M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal